Recce Pharmaceuticals Valuation

Is RCE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RCE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RCE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RCE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RCE?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for RCE. This is calculated by dividing RCE's market cap by their current preferred multiple.
What is RCE's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	AU$120.44m

RCE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	25.2x
Enterprise Value/EBITDA	-7.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RCE's PS Ratio compare to its peers?

The above table shows the PS ratio for RCE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	17.3x
PER Percheron Therapeutics	31.9x	-0.7%	AU$94.7m
AGN Argenica Therapeutics	35.2x	n/a	AU$91.5m
VLS Vita Life Sciences	1.6x	n/a	AU$125.5m
VIT Vitura Health	0.4x	n/a	AU$43.8m
RCE Recce Pharmaceuticals	24x	-2.0%	AU$120.4m

Price-To-Sales vs Peers: RCE is expensive based on its Price-To-Sales Ratio (24x) compared to the peer average (17.3x).

Price to Earnings Ratio vs Industry

How does RCE's PE Ratio compare vs other companies in the AU Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	55.6%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	55.6%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: RCE is expensive based on its Price-To-Sales Ratio (24x) compared to the Australian Pharmaceuticals industry average (5.3x).

Price to Sales Ratio vs Fair Ratio

What is RCE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RCE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	24x
Fair PS Ratio	0.9x

Price-To-Sales vs Fair Ratio: RCE is expensive based on its Price-To-Sales Ratio (24x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.